ABMD 34.24 Abiomed $ABMD Hit a 52 week high of 34.55

New Post Public Reply Private Reply Replies (0) Message Board

Nov 20, 2014 at 10:03 AM

ABMD 34.24 Abiomed $ABMD Hit a 52 week high of 34.55 Closing the day 09:45 at 34.24 -0.38 -1.10% With a day low of 34.09 and a total volume of 8,524.

ABMD Recent Posts: http://investorshangout.com/Abiomed-ABMD-53201/

ABMD Abiomed Recent Headline News

Abiomed and Area Colleges to Host Life Sciences Career Seminars for Growing Number of Student Veterans
GlobeNewswire - 2 hrs 1 min ago
The MedTech and BioTech Veterans Program (MVP) announced today it will host two Student Veteran Re-careering Seminars for student service members, veterans and graduates interested in pursuing careers in the life sciences.
ABMD: 34.17 (-0.45)

ABIOMED Has Returned 40.9% Since SmarTrend Recommendation (ABMD)
Comtex SmarTrend(R) - Wed Nov 19, 9:44AM CST
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on October 28th, 2014 at $24.67. In approximately 3 weeks, ABIOMED has returned 40.94% as of today's recent price of $34.77.
ABMD: 34.17 (-0.45)

ABIOMED Earnings In Retrospect: Up 6.1% in the Last 18 Days (ABMD)
Comtex SmarTrend(R) - Mon Nov 17, 12:42PM CST
When ABIOMED (NASDAQ:ABMD) reported earnings 18 days ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $0.02 on sales of $50.1 million. ABIOMED actually reported earnings of $0.09 per share on sales of $51.9 million, beating EPS estimates by $0.07 and beating revenue estimates by $1.8 million. Shares of ABIOMED have climbed from $31.35 to $33.25, representing a gain of 6.1% since the company reported earnings 18 days ago.
ABMD: 34.17 (-0.45)

Abiomed to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Mon Nov 17, 7:18AM CST
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President & Chief Financial Officer, will present at the Jefferies 2014 Global Healthcare Conference on November 20, 2014 at 10:40 a.m. GMT. The conference will be held at The Waldorf Hilton London in London, UK.
ABMD: 34.17 (-0.45)

Varian Medical (VAR) Down to Strong Sell on Dismal Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:20PM CST
On Nov 14, 2014, Zacks Investment Research downgraded Varian Medical Systems (VAR) to a Zacks Rank #5 (Strong Sell).
ABMD: 34.17 (-0.45), VAR: 87.56 (-0.10), EW: 122.92 (-2.67), ANGO: 16.88 (-0.16)

ABIOMED (ABMD) Stock: Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:33AM CST
ABIOMED (ABMD) Stock: Moving Average Crossover Alert
ABMD: 34.17 (-0.45)

Thoratec (THOR) Down to Strong Sell on Growing Headwinds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:20PM CST
On Nov 11, 2014, Zacks Investment Research downgraded Thoratec Corp. (THOR) to a Zacks Rank #5 (Strong Sell).
ABMD: 34.17 (-0.45), EW: 122.92 (-2.67), THOR: 30.00 (-0.02), ANGO: 16.88 (-0.16)

Abiomed (ABMD) Hits 52-Week High on Strong Q2 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:10AM CST
Shares of Abiomed, Inc. (ABMD) have been on the rise since it reported impressive second-quarter fiscal 2015 (ended Sep 30, 2014) results on Oct 30.
ABMD: 34.17 (-0.45), FLDM: 29.85 (-0.53), GMED: 22.37 (-0.28), ANGO: 16.88 (-0.16)

ABIOMED Shares Up 34.3% Since SmarTrend's Buy Recommendation (ABMD)
Comtex SmarTrend(R) - Wed Nov 12, 9:15AM CST
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on October 28th, 2014 at $24.67. In approximately 2 weeks, ABIOMED has returned 34.28% as of today's recent price of $33.13.
ABMD: 34.17 (-0.45)

Mettler-Toledo (MTD) Tops Q3 Earnings on Revenue Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 8:34AM CST
Mettler-Toledo International Inc. (MTD) reported adjusted earnings per share (EPS) of $2.95 for the third quarter of fiscal 2014, which beat the Zacks Consensus Estimate of $2.86. Adjusted EPS also improved 13% from the year-ago quarter.
ABMD: 34.17 (-0.45), FLDM: 29.85 (-0.53), ANGO: 16.88 (-0.16), MTD: 291.01 (-1.40)

Roka Bioscience (ROKA) in Focus: Stock Surges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:11AM CST
Roka Bioscience, Inc. (ROKA) was a big mover last session, as the company saw its shares rise over 19% on the day.
ABMD: 34.17 (-0.45), ROKA: 3.94 (unch), EW: 122.92 (-2.67), ANGO: 16.88 (-0.16)

OTC Daily Alert Stock Watch - ABIOMED, Inc. (NASDAQ: ABMD)
WorldStockWire - Mon Nov 10, 12:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ABMD: 34.17 (-0.45)

Volcano Posts Narrower-than-Expected Q3 Loss, Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:10AM CST
Despite Volcano (VOLC) provided disappointing revenue guidance for 2014 on account of expected negative foreign exchange impact, management expects accelerated profitability over the near term.
ABMD: 34.17 (-0.45), VOLC: 10.94 (+0.04), EW: 122.92 (-2.67), ANGO: 16.88 (-0.16)

Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:46AM CST
DexCom (DXCM) was a big mover last session, with shares rising over 14% on the day.
ABMD: 34.17 (-0.45), DXCM: 50.59 (+0.11), EW: 122.92 (-2.67), ANGO: 16.88 (-0.16)

VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 108.07 (-1.01), ABMD: 34.17 (-0.45), JNJ: 107.98 (-0.78), AMGN: 162.50 (-0.14), EXAS: 22.57 (-0.04), ARAY: 7.14 (-0.07), HOLX: 26.14 (-0.15), PBYI: 221.01 (-2.31)

Update: Abiomed's Q2 Fiscal 2015 Earnings Remained Impressive
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:40PM CST

ABMD: 34.17 (-0.45)

Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 1:50PM CST
Hologic (HOLX) entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic
ABMD: 34.17 (-0.45), DXCM: 50.59 (+0.11), ANGO: 16.88 (-0.16), HOLX: 26.14 (-0.15)

Thoratec Q3 Earnings & Revenues Lag Estimates, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:00AM CST
Following the earnings release, shares of Thoratec Corp. (THOR) declined approximately 3.5% to close at $26.10 yesterday.
ABMD: 34.17 (-0.45), CYNO: 26.27 (-0.21), THOR: 30.00 (-0.02), ANGO: 16.88 (-0.16)

Abiomed (ABMD) Upgraded From Hold to Buy
at The Street - Fri Nov 07, 8:07AM CST
Abiomed (ABMD) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
ABMD: 34.17 (-0.45)

Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 34.17 (-0.45), DXCM: 50.59 (+0.11), FMI: 24.28 (+0.14), ANGO: 16.88 (-0.16)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Biotech's Future Faces Tight Investment Restrictions

Biotech Investment: Between a Rock and a Hard Place The U.S. Department of the Treasury just threw a curveball at the biotechnology sector with its proposal to shore up the Comprehensive Outbound Investment National Security (COINS) Act. This ain't just another set of lines on a folded napkin; the new rules would put a chokehold on American investments flowing into...

CASEKOO's Spooky Collectibles: Postcards Meet Cases

Here we go with an unexpected twist in the phone accessory game. CASEKOO decided it's time to mix things up this Halloween with something as peculiar as it is intriguing: limited-edition Spooky Season Commemorative Postcards. A Spooky Strategy to Celebrate Ten Years Get this, folks—CASEKOO's looking to mark a decade in the business with more than just confetti and a...

FRP Moto Unveils M3 Mini: High-Tech Wheelie, 55 MPH Speed

Who knew that mini bikes could pack such a punch? Enter the M3 from the folks at FRP Moto. This isn't just another two-wheeler for the kiddie circuit. Nope, this one's got the juice to make even seasoned riders do a double take. We're talking electric power, a top speed of 55 mph, and some snazzy wheelie modes. A Look Under the Hood Get this – the M3 isn’t your...

Concierge Hybrid Choice™: Transforming Patient Care

A New Way to Nurture Patient Relationships This isn't just another cookie-cutter patient care program rolling out—it’s a genuine shake-up in the way doctors connect with their patients. Rishika Kaundal, MD, a dedicated family medicine physician, is pioneering change in Midlothian, Virginia with her Hybrid Choice™ concierge program. This isn't a fluff piece; it's a...

Reel Drops: Eightpoint's New Social Drama App Explored

Mobile Drama: A Quick Escape with Reel Drops In this fast-moving world, where time feels as elusive as a daydream, Eightpoint is shaking up mobile entertainment with its brand-new app, Reel Drops. Based out of George Town, Cayman Islands, this app aims to give viewers a shot at swift, captivating storytelling without the marathon commitment of a binge-watch session. A New...

Aberdeen's Reverse Split: What Investors Need to Know

Tackling Aberdeen's New Playbook Aberdeen Multi-Market Income Fund (NYSE: MMT) is pulling the trigger on a 1-for-4 reverse stock split come November 9, 2026. This isn't your average headline-grabbing move but one that could shake up how MMT trades. It’s a classic case of tidying up shop, aiming to bolster the share price and streamline share trading. No Change in Fund...

Concrete Admixtures Market: A Billion-Dollar Boom

A Look Under the Hood of Concrete Admixtures It's a concrete jungle out there, folks—literally. The once overlooked market of concrete admixtures is gearing up for quite the makeover, projected to hit USD 35.87 billion by 2035. For those of you tuning in, we're talking about chemicals that mix into your average concrete to change its properties. And, believe it or not,...

Medline's MedTrans Rodeo: Honoring Driver Excellence

Rollin' Down the Road of Excellence In the world of healthcare logistics, Medline's MedTrans team isn't just steering trucks—they're steering safety culture and supply chain efficiency. This October, they wrapped up their fourth annual National Truck Rodeo in Mundelein, Illinois. And let me tell you, it was more than just a fancy event. It was about celebrating the real...

Northern Virginia's Housing Inventory Surges Despite Market Pressures

Unexpected Surge in Northern Virginia's Inventory Walking around Fairfax these days, you might feel like you're in a time warp, especially if you're tracking the housing market. See, while the rest of the country's housing market groans under sluggish sales and creeping prices, Northern Virginia's doing a dance of its own. Inventory's ballooning faster than a parade...

Lunit, Summit Tackle Tumor Analysis with AI Platform

Amid whispers of AI revolutionizing every industry, let's zero in on its latest pit stop—oncology R&D. Lunit, shaking hands with Summit Therapeutics, plans to bring artificial intelligence into the tumor microenvironment analysis game, thanks to the Lunit SCOPE IO platform. This isn't just another lab experiment; it's a step towards redefining how we understand cancer's...